Introduction

Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets are a modern and highly effective combination medication used for the management of Type 2 Diabetes Mellitus (T2DM). This dual-action formulation combines Dapagliflozin, an SGLT2 inhibitor, with Metformin Hydrochloride Extended-Release, the gold-standard first-line antidiabetic medicine, to provide comprehensive blood sugar control while supporting cardiovascular and metabolic health.

As Type 2 Diabetes continues to affect millions of people worldwide, healthcare providers increasingly rely on combination therapies that address multiple aspects of glucose regulation. Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets offer a convenient once-daily treatment option that helps lower blood glucose levels, improve insulin sensitivity, support weight management, and reduce the risk of diabetes-related complications.

Whether you are a patient seeking information, a healthcare professional, or a pharmaceutical distributor, understanding the benefits, uses, and safety profile of this combination can help make informed treatment decisions.

What Are Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets?

Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets are prescription medications indicated for adults with Type 2 Diabetes Mellitus whose blood glucose levels are not adequately controlled through diet, exercise, or single-drug therapy alone.

This advanced combination contains:

Dapagliflozin

A Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor that removes excess glucose from the body through urine.

Metformin Hydrochloride Extended-Release

A biguanide antidiabetic agent that improves insulin sensitivity and reduces glucose production in the liver.

Together, these ingredients provide complementary blood sugar control while offering additional metabolic and cardiovascular benefits.

How Does Dapagliflozin and Metformin Hydrochloride Extended-Release Work?

The effectiveness of this combination lies in the unique mechanisms of both active ingredients.

How Dapagliflozin Works

Dapagliflozin belongs to the SGLT2 inhibitor class of medications.

Mechanism of Action

The kidneys normally filter glucose and reabsorb it back into the bloodstream. Dapagliflozin blocks the SGLT2 proteins responsible for this reabsorption.

As a result:

• Excess glucose is excreted through urine
• Blood sugar levels decrease
• Calorie loss occurs through glucose elimination
• Body weight may improve
• Blood pressure may be modestly reduced

This mechanism works independently of insulin production.

How Metformin Hydrochloride Extended-Release Works

Metformin is one of the most prescribed diabetes medications worldwide.

Mechanism of Action

Metformin helps control blood sugar by:

• Reducing glucose production in the liver
• Improving insulin sensitivity
• Enhancing glucose uptake by muscles
• Decreasing intestinal glucose absorption
• Supporting stable blood sugar levels

The extended-release technology provides sustained therapeutic action throughout the day.

Combined Benefits

When combined, Dapagliflozin and Metformin ER:

• Lower fasting blood sugar
• Improve post-meal glucose control
• Reduce HbA1c levels
• Support weight management
• Improve insulin sensitivity
• Provide long-term diabetes management

What Is Dapagliflozin and Metformin Hydrochloride Extended-Release Used For?

1. Type 2 Diabetes Mellitus

The primary indication is the treatment and management of Type 2 Diabetes in adults.

This combination helps patients achieve better glycemic control when lifestyle changes alone are insufficient.

2. HbA1c Reduction

The medication helps lower HbA1c levels, which reflect average blood glucose control over approximately three months.

Lower HbA1c levels are associated with fewer diabetes-related complications.

3. Blood Sugar Management

The combination effectively controls:

• Fasting blood glucose
• Post-meal blood glucose
• Daily glucose fluctuations

4. Weight Management Support

Unlike some diabetes medications associated with weight gain, Dapagliflozin may contribute to modest weight reduction through urinary glucose excretion.

5. Cardiovascular Risk Management

Dapagliflozin has demonstrated cardiovascular benefits in certain patients with Type 2 Diabetes and cardiovascular disease risk factors.

Key Benefits of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets

Dual Mechanism of Action

The combination targets multiple pathways involved in glucose regulation.

Benefits include:

• Improved blood sugar control
• Better metabolic outcomes
• Enhanced treatment effectiveness

Effective HbA1c Reduction

Clinical studies have shown meaningful reductions in HbA1c levels with Dapagliflozin and Metformin combination therapy.

Supports Healthy Weight

Dapagliflozin promotes glucose elimination through urine, which may assist with weight management.

Patients often appreciate the potential for weight-neutral or weight-reducing effects.

Improved Insulin Sensitivity

Metformin helps the body utilize insulin more efficiently, reducing insulin resistance.

Convenient Once-Daily Dosing

The extended-release formulation allows:

• Simplified treatment
• Better adherence
• Consistent glucose control

Lower Risk of Hypoglycemia

When used appropriately without certain other antidiabetic medications, the risk of severe hypoglycemia is generally lower compared to some alternative therapies.

Cardiovascular and Renal Benefits

Emerging evidence suggests Dapagliflozin may support:

• Heart health
• Kidney protection
• Reduced hospitalization for heart failure in appropriate patients

Long-Term Diabetes Management

This combination is suitable for ongoing diabetes care when prescribed and monitored appropriately.

Why Healthcare Professionals Prefer Dapagliflozin and Metformin ER

Healthcare providers frequently recommend this combination because it offers:

• Proven efficacy
• Comprehensive glucose control
• Weight management support
• Cardiovascular advantages
• Improved patient compliance
• Convenient dosing schedule

These advantages make it a valuable option in modern diabetes treatment protocols.

Who Should Use Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets?

This medication may be prescribed for:

• Adults with Type 2 Diabetes Mellitus
• Patients inadequately controlled on Metformin alone
• Individuals requiring combination therapy
• Patients with elevated HbA1c levels
• Overweight diabetic patients seeking improved metabolic outcomes

Treatment should always be based on physician evaluation and individualized medical needs.

Dapagliflozin and Metformin ER Dosage

Dosage depends on:

• Current blood glucose levels
• HbA1c results
• Kidney function
• Previous diabetes treatment
• Individual response

Important Administration Guidelines

• Take exactly as prescribed.
• Usually taken once daily with food.
• Swallow tablets whole.
• Do not crush, chew, or split extended-release tablets.
• Maintain regular blood sugar monitoring.

Blood Glucose Monitoring

Routine monitoring helps evaluate treatment effectiveness and supports informed clinical decisions.

Weight Management

Maintaining a healthy weight improves overall diabetes outcomes and metabolic health.

Side Effects of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets

Like all medications, side effects may occur.Common Side Effects

Increased Urination

Due to glucose excretion through urine, patients may experience:

• Frequent urination
• Increased thirst

Gastrointestinal Symptoms

Most commonly related to Metformin:

• Nausea
• Diarrhea
• Abdominal discomfort
• Loss of appetite

The extended-release formulation often improves gastrointestinal tolerability.

Urinary Tract Infections

Some individuals may experience:

• Burning during urination
• Increased urinary frequency
• Urinary discomfort

Genital Fungal Infections

Dapagliflozin may increase the risk of yeast infections in susceptible individuals.

Serious Side Effects

Seek immediate medical attention if symptoms such as the following occur:

Severe Dehydration

Symptoms may include:

• Dizziness
• Weakness
• Low blood pressure

Kidney Problems

Report any unusual changes in urination or swelling.

Severe Allergic Reactions

Symptoms include:

• Facial swelling
• Difficulty breathing
• Severe rash

Lactic Acidosis (Rare)

Metformin-associated lactic acidosis is rare but serious.

Symptoms include:

• Extreme fatigue
• Rapid breathing
• Severe weakness
• Persistent nausea

Immediate medical care is required.

Precautions and Warnings

Kidney Function

Patients with kidney impairment require careful evaluation before treatment initiation.

Liver Disease

Use cautiously in patients with significant liver disorders.

Alcohol Consumption

Excessive alcohol use should generally be avoided because it may increase certain risks associated with Metformin.

Pregnancy and Breastfeeding

Consult your healthcare provider before using this medication during pregnancy or breastfeeding.

Elderly Patients

Additional monitoring may be recommended due to age-related changes in kidney function.

Frequently Asked Questions

What is Dapagliflozin and Metformin Hydrochloride Extended-Release used for?

It is used to improve blood sugar control in adults with Type 2 Diabetes Mellitus.

Does it help with weight loss?

Many patients experience modest weight reduction due to urinary glucose excretion associated with Dapagliflozin.

Can it cure diabetes?

No. It helps manage diabetes effectively but does not cure the disease.

How long does it take to work?

Blood sugar improvements may begin within days, while HbA1c improvements are typically observed over several weeks to months.

Should it be taken with food?

Yes. Taking the medication with food may improve tolerability and reduce gastrointestinal side effects.

 

Brand Name: GLIDAPAFLOZIN M 10/500 (Steris Healthcare Pvt Ltd)

Composition Name: Dapagliflozin 10 mg & Metformin Hydrochloride (ER) 500 mg

Formulation: Extended-Release (ER) Tablet

Pack Size: 4 x 15 Tablets

Marketed By: Steris Healthcare Pvt Ltd

Regulatory Standard: WHO-GMP Certified Manufacturing Facility

Therapeutic Category: Anti-Diabetic Medicine

Indication: Management of Type 2 Diabetes Mellitus

Schedule: Valid Prescription Required (Prescription Only Medicine)

If You Need More Information About  GLIDAPAFLOZIN M 10/500   Click here